Feasibility study for collection of HER2 data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program central cancer registries

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 1, 2010, Pages 144-147

  Reichman, Marsha E ^a   Altekruse, Sean ^a   Li, Christopher I ^b   Chen, Vivien W ^c   Deapen, Dennis ^d   Potts, Mary ^b   Wu, Xiao Cheng ^c   Morrell, Donna ^d   Hafterson, Jennifer ^b   Phipps, Amanda I ^b   Harlan, Linda C ^a   Ries, Lynn G ^a   Edwards, Brenda K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Louisiana Tumor Registry   (United States)

^d Los Angeles Surveillance Epidemiology and End Results Cancer Registry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL;

AGED; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; REGISTRIES; SEER PROGRAM; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 74549131545     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0807     Document Type: Article

References (8)

1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
2. Andrulis IL, Bull SB, Blackstein ME, et al. Toronto Breast Cancer Study Group. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1998;16:1340-9.
3. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354:2103-11.
4. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-8.
5. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 2008; 112:737-47.
6. Barrett C, Magee H, O'Toole D, Daly S, Jeffers M. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol 2007;60:690-3.
7. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4.
8. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598-607.